Chemotherapy response rates in recurrent/progressive pediatric glioma; Results of a systematic review

Michael Huncharek, Lamar Wheeler, Ronald McGarry, J. F. Geschwind

Research output: Contribution to journalArticle

Abstract

The optimum treatment strategy for recurrent childhood glioma is unknown. This report presents a systematic analysis of the currently available clinical data on chemotherapeutic management of this disease. A study protocol was prospectively developed outlining the objectives and methods of analysis including literature search strategy, eligibility criteria for published trials to be included, key data elements to be extracted and a plan for statistical analysis. Summary statistics were analyzed for the primary outcome variables. Data on recognized prognostic factors were recorded in order to adjust the outcome measures for these factors. A total of 27 non-randomized clinical trials were included in the analysis. Studies were stratified into 6 chemotherapy classes based on the frequency of drug used across studies. Average median response (complete + partial) across all drug categories was approximately 14% (range 10.4-23.5%). Adding patients with stable disease to complete and partial responders at least doubled average median response rates. Time to tumor progression ranged from 29.4 weeks to 49.7 weeks. The most frequently used drugs were the platinum analogs which demonstrated a mean TTP of 42.0 = /-23.4 weeks. Small sample sizes and the overall poor quality of the available data precluded definitive conclusions regarding the clinical impact of the various drug classes on the natural history of this disease.

Original languageEnglish (US)
Pages (from-to)3569-3574
Number of pages6
JournalAnticancer Research
Volume19
Issue number4 C
StatePublished - 1999

Fingerprint

Glioma
Pediatrics
Drug Therapy
Pharmaceutical Preparations
Disease Management
Platinum
Sample Size
Outcome Assessment (Health Care)
Neoplasms
Therapeutics

Keywords

  • Clinical epidemiology
  • Combined modality therapy
  • Meta-analysis
  • Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Huncharek, M., Wheeler, L., McGarry, R., & Geschwind, J. F. (1999). Chemotherapy response rates in recurrent/progressive pediatric glioma; Results of a systematic review. Anticancer Research, 19(4 C), 3569-3574.

Chemotherapy response rates in recurrent/progressive pediatric glioma; Results of a systematic review. / Huncharek, Michael; Wheeler, Lamar; McGarry, Ronald; Geschwind, J. F.

In: Anticancer Research, Vol. 19, No. 4 C, 1999, p. 3569-3574.

Research output: Contribution to journalArticle

Huncharek, M, Wheeler, L, McGarry, R & Geschwind, JF 1999, 'Chemotherapy response rates in recurrent/progressive pediatric glioma; Results of a systematic review', Anticancer Research, vol. 19, no. 4 C, pp. 3569-3574.
Huncharek, Michael ; Wheeler, Lamar ; McGarry, Ronald ; Geschwind, J. F. / Chemotherapy response rates in recurrent/progressive pediatric glioma; Results of a systematic review. In: Anticancer Research. 1999 ; Vol. 19, No. 4 C. pp. 3569-3574.
@article{bcf31b45698b44beaca9e04fe428df34,
title = "Chemotherapy response rates in recurrent/progressive pediatric glioma; Results of a systematic review",
abstract = "The optimum treatment strategy for recurrent childhood glioma is unknown. This report presents a systematic analysis of the currently available clinical data on chemotherapeutic management of this disease. A study protocol was prospectively developed outlining the objectives and methods of analysis including literature search strategy, eligibility criteria for published trials to be included, key data elements to be extracted and a plan for statistical analysis. Summary statistics were analyzed for the primary outcome variables. Data on recognized prognostic factors were recorded in order to adjust the outcome measures for these factors. A total of 27 non-randomized clinical trials were included in the analysis. Studies were stratified into 6 chemotherapy classes based on the frequency of drug used across studies. Average median response (complete + partial) across all drug categories was approximately 14{\%} (range 10.4-23.5{\%}). Adding patients with stable disease to complete and partial responders at least doubled average median response rates. Time to tumor progression ranged from 29.4 weeks to 49.7 weeks. The most frequently used drugs were the platinum analogs which demonstrated a mean TTP of 42.0 = /-23.4 weeks. Small sample sizes and the overall poor quality of the available data precluded definitive conclusions regarding the clinical impact of the various drug classes on the natural history of this disease.",
keywords = "Clinical epidemiology, Combined modality therapy, Meta-analysis, Survival",
author = "Michael Huncharek and Lamar Wheeler and Ronald McGarry and Geschwind, {J. F.}",
year = "1999",
language = "English (US)",
volume = "19",
pages = "3569--3574",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "4 C",

}

TY - JOUR

T1 - Chemotherapy response rates in recurrent/progressive pediatric glioma; Results of a systematic review

AU - Huncharek, Michael

AU - Wheeler, Lamar

AU - McGarry, Ronald

AU - Geschwind, J. F.

PY - 1999

Y1 - 1999

N2 - The optimum treatment strategy for recurrent childhood glioma is unknown. This report presents a systematic analysis of the currently available clinical data on chemotherapeutic management of this disease. A study protocol was prospectively developed outlining the objectives and methods of analysis including literature search strategy, eligibility criteria for published trials to be included, key data elements to be extracted and a plan for statistical analysis. Summary statistics were analyzed for the primary outcome variables. Data on recognized prognostic factors were recorded in order to adjust the outcome measures for these factors. A total of 27 non-randomized clinical trials were included in the analysis. Studies were stratified into 6 chemotherapy classes based on the frequency of drug used across studies. Average median response (complete + partial) across all drug categories was approximately 14% (range 10.4-23.5%). Adding patients with stable disease to complete and partial responders at least doubled average median response rates. Time to tumor progression ranged from 29.4 weeks to 49.7 weeks. The most frequently used drugs were the platinum analogs which demonstrated a mean TTP of 42.0 = /-23.4 weeks. Small sample sizes and the overall poor quality of the available data precluded definitive conclusions regarding the clinical impact of the various drug classes on the natural history of this disease.

AB - The optimum treatment strategy for recurrent childhood glioma is unknown. This report presents a systematic analysis of the currently available clinical data on chemotherapeutic management of this disease. A study protocol was prospectively developed outlining the objectives and methods of analysis including literature search strategy, eligibility criteria for published trials to be included, key data elements to be extracted and a plan for statistical analysis. Summary statistics were analyzed for the primary outcome variables. Data on recognized prognostic factors were recorded in order to adjust the outcome measures for these factors. A total of 27 non-randomized clinical trials were included in the analysis. Studies were stratified into 6 chemotherapy classes based on the frequency of drug used across studies. Average median response (complete + partial) across all drug categories was approximately 14% (range 10.4-23.5%). Adding patients with stable disease to complete and partial responders at least doubled average median response rates. Time to tumor progression ranged from 29.4 weeks to 49.7 weeks. The most frequently used drugs were the platinum analogs which demonstrated a mean TTP of 42.0 = /-23.4 weeks. Small sample sizes and the overall poor quality of the available data precluded definitive conclusions regarding the clinical impact of the various drug classes on the natural history of this disease.

KW - Clinical epidemiology

KW - Combined modality therapy

KW - Meta-analysis

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=0033405751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033405751&partnerID=8YFLogxK

M3 - Article

C2 - 10629654

AN - SCOPUS:0033405751

VL - 19

SP - 3569

EP - 3574

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 4 C

ER -